Table 1.
Baseline characteristics of 240 chronic myeloid leukemia patients
|
Total N = 240 (100%) |
KIR2DL5B
negative N = 180 (75%) |
KIR2DL5B
positive N = 60 (25%) |
P‐value | |
|---|---|---|---|---|
| Clinical trial‐N (%) | ||||
| STIM1 | 49 (20.4) | 39 (21.7) | 10 (16.7) | 0.41 |
| STIM2 | 191 (79.6) | 141 (78.3) | 50 (83.3) | |
| Age at discontinuation of imatinib (years) | ||||
| Median (IQR) | 60.8 (51.4‐70.7) | 60.6 (51.1‐69.1) | 64.1 (51.5‐72.7) | 0.71 |
| Range | 24.2;91.1 | 24.2;91.1 | 27.0;83.9 | |
| Gender‐N (%) | ||||
| Male | 114 (47.5) | 82 (45.6) | 32 (53.3) | 0.30 |
| Female | 126 (52.5) | 98 (54.4) | 28 (46.7) | |
| Sokal risk score at diagnosis‐N (%) | ||||
| Low | 107 (44.8) | 83 (46.1) | 24 (40.7) | 0.75 |
| Intermediate | 100 (41.8) | 73 (40.6) | 27 (45.8) | |
| High | 32 (13.4) | 24 (13.3) | 8 (13.6) | |
| Imatinib duration (years) | ||||
| Median (IQR) | 6.0 (4.6‐7.9) | 6.0 (4.6‐8.0) | 5.8 (4.4‐7.4) | 0.28 |
| Range | 2.9;12.5 | 2.9;12.0 | 3.2;12.5 | |
| Time to first DMR (months) | ||||
| Median (IQR) | 25.8 (16.5‐46.8) | 25.9 (17.2‐47.4) | 25.0 (15.4‐42.4) | 0.77 |
| Range | 2.7;104.6 | 2.7;104.6 | 5.5;83.0 | |
| First DMR duration (years)a | ||||
| Median (IQR) | 3.1 (2.4‐4.4) | 3.1 (2.4‐4.3) | 3.1 (2.4‐4.5) | 0.93 |
| Range | 1.9;10.4 | 2.0;10.4 | 1.9;9.7 | |
| Molecular recurrence‐N (%)b | 128 (53.3) | 100 (55.6) | 28 (46.7) | 0.23 |
| Deaths‐N (%) | 3 (1.3) | 2 (1.1) | 1 (1.7) | 1.00 |
Abbreviations: DMR, deep molecular remission; KIR, killer immunoglobulin‐like receptors; IQR, interquartile range.
a
Before discontinuation of imatinib.
b
After discontinuation of imatinib.